In 1998, celecoxib was approved as the 1st selective COX-2 inhibitors.38 Celecoxib is a member of the coxib family, which included in the anatomical therapeutic chemical classification system; it is made of a 3-dimensional structure design of molecules with COX-2 selectivity.39 Celecoxib is a sulfonamide and can produce severe hypersensitivity reactions in patients with sulfonamide allergies, resulting in AEs that include asthma, nasal polyps, and rhinitis.40 Here, PTGS2 is linked to nasal cavity polyp.